Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
- PMID: 33526412
- DOI: 10.1136/bmj.n296
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Similar articles
-
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7. BMC Infect Dis. 2014. PMID: 25466778 Free PMC article. Clinical Trial.
-
COVID-19 update: Novavax vaccine for 2024-2025.Med Lett Drugs Ther. 2024 Oct 28;66(1714):175-176. doi: 10.58347/tml.2024.1714d. Med Lett Drugs Ther. 2024. PMID: 39466309 No abstract available.
-
COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.Acta Med Indones. 2020 Oct;52(4):388-412. Acta Med Indones. 2020. PMID: 33377885 Review.
-
Covid-19: Whatever happened to the Novavax vaccine?BMJ. 2021 Dec 8;375:n2965. doi: 10.1136/bmj.n2965. BMJ. 2021. PMID: 34880071 No abstract available.
-
Combination vaccines in the South African setting.Vaccine. 2012 Sep 7;30 Suppl 3:C38-44. doi: 10.1016/j.vaccine.2012.05.001. Vaccine. 2012. PMID: 22939020 Review.
Cited by
-
Interpreting vaccine efficacy trial results for infection and transmission.medRxiv [Preprint]. 2021 May 27:2021.02.25.21252415. doi: 10.1101/2021.02.25.21252415. medRxiv. 2021. Update in: Vaccine. 2021 Jul 5;39(30):4082-4088. doi: 10.1016/j.vaccine.2021.06.011. PMID: 33655276 Free PMC article. Updated. Preprint.
-
Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters.EBioMedicine. 2021 Jun;68:103403. doi: 10.1016/j.ebiom.2021.103403. Epub 2021 May 25. EBioMedicine. 2021. PMID: 34049240 Free PMC article.
-
Analysis of SARS-CoV-2 viral loads in stool samples and nasopharyngeal swabs from COVID-19 patients in the United Arab Emirates.PLoS One. 2022 Sep 22;17(9):e0274961. doi: 10.1371/journal.pone.0274961. eCollection 2022. PLoS One. 2022. PMID: 36137134 Free PMC article.
-
Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate.Pharmaceutics. 2022 Apr 13;14(4):854. doi: 10.3390/pharmaceutics14040854. Pharmaceutics. 2022. PMID: 35456687 Free PMC article.
-
SARS-CoV-2 variants, immune escape, and countermeasures.Front Med. 2022 Apr;16(2):196-207. doi: 10.1007/s11684-021-0906-x. Epub 2022 Mar 6. Front Med. 2022. PMID: 35253097 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources